Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00115011 · ClinicalTrials.gov registry record · Phase 4
Escitalopram for the Treatment of Self-Injurious Skin Picking
A Phase 4 study of Impulse Control Disorders, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00115011: Completed Phase 4 study of Impulse Control Disorders, sponsored by Massachusetts General Hospital.
NCT00115011 is a Phase 4 study of Impulse Control Disorders that has completed, run by Massachusetts General Hospital. The registered enrollment target is 30 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00115011, a Phase 4 study of Impulse Control Disorders, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the effectiveness of escitalopram in treating self-injurious skin picking.
Conditions Studied
Interventions
- DRUG Escitalopram
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2002-09 |
| Est. Completion | 2005-11 |
| Phase | Phase 4 |
What the finished NCT00115011 record still lists
NCT00115011 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Impulse Control Disorders appearing as the primary indexed condition, and to 1 intervention - of which Escitalopram is the first listed.
NCT00115011 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00115011 about?
NCT00115011 is a clinical study titled "Escitalopram for the Treatment of Self-Injurious Skin Picking". The purpose of this study is to determine the effectiveness of escitalopram in treating self-injurious skin picking.
What is the current status of trial NCT00115011?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2002-09. Estimated completion is 2005-11.
What conditions does trial NCT00115011 study?
This clinical trial studies the following conditions: Impulse Control Disorders.
What interventions are being tested in trial NCT00115011?
The interventions under investigation include: Escitalopram (DRUG).
Who is sponsoring clinical trial NCT00115011?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00115011 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Impulse Control Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00115011's enrollment target sits among peer trials
30 1552nd of 2000 higher than 368 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia